Oxford BioMedica plc (LON:OXB) insider Lorenzo Tallarigo acquired 29,365 shares of the stock in a transaction on Wednesday, December 20th. The shares were purchased at an average cost of GBX 9 ($0.12) per share, with a total value of £2,642.85 ($3,557.00).

Lorenzo Tallarigo also recently made the following trade(s):

  • On Thursday, November 23rd, Lorenzo Tallarigo acquired 30,861 shares of Oxford BioMedica stock. The shares were purchased at an average cost of GBX 9 ($0.12) per share, with a total value of £2,777.49 ($3,738.21).
  • On Monday, October 23rd, Lorenzo Tallarigo acquired 30,436 shares of Oxford BioMedica stock. The shares were purchased at an average cost of GBX 9 ($0.12) per share, with a total value of £2,739.24 ($3,686.73).
  • On Friday, September 22nd, Lorenzo Tallarigo acquired 29,685 shares of Oxford BioMedica stock. The shares were purchased at an average cost of GBX 9 ($0.12) per share, with a total value of £2,671.65 ($3,595.76).

Oxford BioMedica plc (OXB) opened at GBX 9.03 ($0.12) on Wednesday. Oxford BioMedica plc has a twelve month low of GBX 3.77 ($0.05) and a twelve month high of GBX 11.25 ($0.15).

Several brokerages have commented on OXB. N+1 Singer raised their price objective on Oxford BioMedica from GBX 8.70 ($0.12) to GBX 10.20 ($0.14) and gave the company a “hold” rating in a research report on Thursday, August 31st. Peel Hunt assumed coverage on Oxford BioMedica in a report on Tuesday, September 19th. They set a “buy” rating and a GBX 13 ($0.17) price target for the company. Finally, Jefferies Group restated a “buy” rating and set a GBX 13 ($0.17) price target on shares of Oxford BioMedica in a report on Thursday, August 31st.

TRADEMARK VIOLATION NOTICE: “Lorenzo Tallarigo Acquires 29,365 Shares of Oxford BioMedica plc (OXB) Stock” was first reported by American Banking News and is the sole property of of American Banking News. If you are reading this report on another website, it was copied illegally and reposted in violation of US & international trademark & copyright laws. The correct version of this report can be read at https://www.americanbankingnews.com/2017/12/20/lorenzo-tallarigo-acquires-29365-shares-of-oxford-biomedica-plc-oxb-stock.html.

Oxford BioMedica Company Profile

Oxford BioMedica plc is a gene and cell therapy company. The Company is engaged in lentiviral vector and cell therapy research, development and production. The Company’s segments include Partnering, and R&D. The Partnering segment provides lentiviral vector bioprocessing and process development services to partners.

Insider Buying and Selling by Quarter for Oxford BioMedica (LON:OXB)

Receive News & Ratings for Oxford BioMedica Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oxford BioMedica and related companies with MarketBeat.com's FREE daily email newsletter.